At Steinfl + Bruno, we take a different approach to how we observe our professional surroundings, thinking from the end to deliver the best possible work product. As patent designers, we challenge the traditional ways of viewing our environment, looking beyond what is given. We focus on taking a different point of view to get a deep understanding of how to protect the innovation. Our goal is that of thinking from the end so to provide the innovators with IP protection that can become an engine of growth for their operation, opening possibilities and always, always striving for excellence.
May 14, 2019
Patenting artificial intelligence? Biotech might show us the wayread more
Patents - May 14, 2019
Patenting artificial intelligence? Biotech might show us the way
As innovations involving artificial intelligence become more and more prevalent, some issues arise in patenting these innovations. These will become even more pronounced as AI advances to the level where the AI implementations might begin producing inventions themselves.
Why biotechnology? Because biotechnology once faced similar challenges in terms of its compatibility with the existing patent law system.
Similarly to AI, biotechnology deals with elements independent of human intervention (natural process product in biotech, and certain computations/calculations for AI such as AI neural networks), forming a sort of “black box”, which is an integral part of the technology even if the related content of it is, all or in part, unknown to the user.
This fact is at the core of the many issues stemming from the need to ensure not only adequacy of disclosure and assessment of non-obviousness/inventive step but also inventorship and patent eligibility, as the “black box’ relates to the question of eligibility of subject matter in many jurisdictions (e.g. laws of nature and mathematical relationships).
As a consequence, finding, for AI, solutions that are consistent with the solutions adopted for biotech would provide a consistency in the patent legal system. Providing a consistent approach to the protection of both technologies safeguards the legal principles regulating the patenting of innovations, which should be independent of the technology involved.
The challenge for the patent practitioner is that of treating similar features similarly and different features differently for each technology.
Read the full article on IPLaw360 for extended analysis from S+B founder and partner Enrica Bruno and patent attorney Brian Cash about why inventions produced from sentient AI could prove trickier to patent, how secure deposits could aid nonobviousness/inventive step analysis, and whether the practice regarding natural products could also be applied to AI.
May 13, 2019
Approaching 35 USC 101 from the other sideread more
Patents - May 13, 2019
Approaching 35 USC 101 from the other side
by Alessandro Steinfl and Brian J. Cash
On January 7, 2019, the USPTO introduced a 2019 Revised Patent Subject Matter Eligibility Guidance in the Federal Register.
There have been a number of resources put out by the USPTO in helping practitioners understand the changes, but we thought it would be useful to offer some advice of our own along with a flowchart from the practitioner’s point of view, particularly the point of view of a practitioner who has received a rejection from an examiner.
The first step is, of course, a consideration of a step 1 rejection: that is, the examiner is rejecting the claims not on an Alice-based factor, but on a traditional “is the claim in a statutory category” basis.
If the examiner includes rejections based on Alice (i.e. step 2A and step 2B), then you have a few questions to answer. For the first half of 2A, you have to see if the claim recites anything that can be a judicial exception falls in one of the appropriate categories.The next step would be to address if the claim is integrating the abstract idea into a practical application.
Then there are the 2B (“something significantly more”) arguments to make, though there are several post-Alice guidance changes to keep in mind.
For a breakdown of those changes and a primer on how to approach them successfully, read the full article on Law360 by Steinfl+Bruno partner Alessandro Steinfl and patent attorney Brian J. Cash.
May 12, 2019
Mission Impossible? How to Effectively Draft the Background Section of a Patent Specification in Compliance with Both USPTO and EPO Practiceread more
Patents - May 12, 2019
Mission Impossible? How to Effectively Draft the Background Section of a Patent Specification in Compliance with Both USPTO and EPO Practice
Preparation of the background section of a specification that complies with the requirements of both U.S. Patent and Trademark Office (USPTO) and European Patent Office (EPO) requirements is tricky.
In U.S. patent applications, statements made in the background section can be considered an admission of prior art. Additionally, statements made in the background section of an issued U.S. patent can not only be used against expert testimony that describes the prior art differently and during claim construction, but also can have a limiting effect on claim interpretation.
In contrast, statements made in the background section of EPO applications that discuss deficiencies and technical problems present in the prior art are expected to be included.
This apparent dichotomy in rules often results in lengthy background sections for applications to be filed at the EPO, while many U.S. practitioners keep them short and sweet.
Read the full article on IPWatchdog.com for Steinfl+Bruno founder and partner Enrica Bruno’s analysis of patent application guidelines in the United States and Europe, and learn why she thinks much of the common wisdom surrounding the drafting of background sections is misguided.
May 04, 2018
The difference between theoretically and practically: Correcting Assignment Coversheets at the USPTOread more
S+B - May 04, 2018
The difference between theoretically and practically: Correcting Assignment Coversheets at the USPTO
This is why the USPTO rules and guidelines provide procedures to correct mistakes, in particular typos and other mistakes of clerical nature at various stages of the prosecution (see, for examples, 37 CFR 1.76(c) Correction of ADS, PCT Rule 91.1 Rectification of Obvious Mistakes, 37 CFR 1.121(b) Amendments to Specification, 37 CFR 1.323 Certificate of Correction of Applicant’s Mistake, and 37 CFR 3.34 Correction of Cover Sheet Errors).
These procedures typically work well unless one has to deal with correction of assignment cover pages. In those situations, a user is faced with an apparent disconnect between how the MPEP instructs that the USPTO handle requests for a correction to an assignment coversheet and how the USPTO Assignment Branch actually handles those requests.
In theory (i.e., MPEP 323.01(a); 37 CFR 3.34), the requirements for correcting a cover sheet are to provide a) a copy of the originally recorded assignment document, b) a corrected cover sheet, and c) the payment of a fee. Also the request can be filed by mail (see MPEP 302.08) or fax (see MPEP 302.09). If you want to file the correction electronically with EPAS, the MPEP instructs to check the box marked “other” under “nature of conveyance” and fill in reel/frame and the nature of the correction. Simple, right?
In practice, requests for correction of Notices of Recordation of Assignment (NORA) by mail and fax and request filed by EPAS checking the box marked “other” in accordance with the MPEP procedure can be inexplicably rejected by the USPTO Assignment Branch.
It appears from exchanges with the USPTO Assignment Branch Examiners that the main reason is the presence of a de facto EPAS-centered procedure at the USPTO Assignment Branch and an EPAS configuration that makes the option indicated by the MPEP impractical.
In particular, it appears that the only practical way to perform the correction of a NORA incorrect due to information of the cover page, is to file the related request as a request for a “corrective assignment”, which is a different option than “other” and refers to a completely different situation (an error in the recorded assignment, see MPEP 323).
This is inexplicable because EPAS is a system that is specifically tailored for Assignment Branch requests, and yet EPAS cannot handle a type of request that is so common that the request has its own MPEP section.
There should be no difficulty in having a separate button under “nature of conveyance” labeled “Correction to Cover Sheet” with text fields for the required information, just like the “Corrective Assignment” button.
This would aid the public in having an evident-on-its-face selection for addressing that specific request and it would aid the Assignment Branch in removing the ambiguity in the rules regarding how they should process such requests.
Regardless, USPTO Assignment Branch’s practice should allow Applicants to file requests by mail and/or fax as these routes are specifically indicated in the MPEP.
If that turned out to be impractical, a modification of the USPTO guidance, rules (MPEP and CFR) and/or practice so that they align and clearly address different situations (such as a correction of a cover page and a correction of an assignment) would also help users and Examiners.
Meanwhile, it seems that the best way to handle these corrections is to communicate with the USPTO Assignment Branch to ensure streamlining of a procedure that should only be a minor bump on the road.
We surely hope to soon see an improved EPAS system for a speedy processing of recordation requests in line with the USPTO rules.
Feb 27, 2018
Frontiers of Technology in Implantable Medical Devices: Neuromodulationread more
Technology - February 27, 2018
Frontiers of Technology in Implantable Medical Devices: Neuromodulation
One of the biggest challenges in the development of medical devices is the reduction of physical size of the devices and instruments. One technology area that has met this challenge is neuromodulation. Neuromodulation devices may be applied to affect the five senses, muscle control and other functions within the body. These devices included an array of evolving technology, such as computer chips, electrodes, hardware, electrical signals and other synthetic items that interact with the human body. The problems facing entrepreneurs and start-ups and established medical device companies are myriad, the physical size being only one factor.
Technological developments have blurred the line between traditional electrical, chemical, mechanical, biological and applied physics academics. Accordingly, the material science integrates into physics, the chemistry integrates into electronics and the biology integrates into computer algorithms. Medical devices for neuromodulation are pushing the boundaries of technology to produce safe and effective devices beyond traditional physiological areas, such as into the brain, spine and peripheral organs.
Example technological breakthroughs currently being commercialized include a bionic eye having a retinal implant providing electrical stimulation of the retina to induce visual perception in blind individuals with severe to profound Retinitis Pigmentosa. Although the resolution does not match that of a CCD camera or CMOS image sensors popular in camera phones, the pixel array in the bionic eye is sufficient for the user to see and recognize another human, traverse a predefined walking path and even snow ski. Second Sight Medical Products, Inc. of Sylmar, CA has made significant strides in this area.
Interesting examples can be found in two videos about patients using their new bionic eyes and a captivating interview with a blind skier.
Other technologies are focused on the design and development of devices to help restore function and movement in patients with paralysis, for example, non-invasive spinal cord neuromodulator systems. NeuroRecovery Technologies, Inc. is at the forefront in this area, providing patients the ability to restore voluntary movement to their hands and legs and to stand on his/her own feet after catastrophic spinal injury.
Other companies, such as Boston Scientific, are using advanced micro stimulation technologies to develop devices related to spinal cord stimulation for the treatment of chronic pain and deep brain stimulation for movement disorders.
Related research at the University of California, Irvine is being directed to neural engineering, biomedical signal processing and pattern recognition, biological neural network modeling, and biomedical devices and sensors.
As a result of the technological advancements in neuromodulation, companies are developing medical device products and technologies that transform patients’ lives – in our view, a laudatory goal of medical device innovation and a major benefit to society. We commend these researchers, entrepreneurs and medical device companies in bringing their passion to advance technology that surely excites us all and provides hope for a better future in applied medicine directed to neuromodulation.
In November 2017, the Caltech Entrepreneurs Forum in Pasadena produced the program “Neuromodulation – Changing Lives with Direct Nerve-to-Device Connections”. The program explored the near and intermediate term prospects for researching, developing and implementing devices that interact with the body’s neural network. The speakers shared their views on the opportunities and challenges of the field and provided their views of the future in medical devices directed to neuromodulation.
There is much work to be done to bring neuromodulation devices into the mainstream of medicine. Barriers still exist in size reduction, doctor adoption and recommendation, patient acceptance and financial reimbursement. At Steinfl+Bruno, we will be monitoring and participating, as the occasion arises, in this and other exciting technological fields of medicine.
Feb 09, 2018
S+B Best Practices: Filing Drillsread more
S+B - February 09, 2018
S+B Best Practices: Filing Drills
Filing electronically with the USPTO has become the standard practice for nearly all patent practitioners these days (over 98% in 2016, according to https://www.uspto.gov/learning-and-resources/newsletter/inventors-eye/using-efs-web-5-electronic-filing-pitfalls-and-how).
Not only does this practice line up nicely with today’s focus on electronic communications and data transfer, the USPTO provides some financial incentives in the form of some reduced fees. Even with the numerous issues and complaints about the current electronic filing system (EFS), most would agree it is better than the old method of putting printouts of the documents in an envelope and mailing it to Alexandria, VA. The EFS method is clearly the best way to file your application.
Unless the system goes down.
On December 22, 2016, it did just that in a major way. Not only did EFS go down, and stay down for a long time, but the sudden inrushes of attempts to file office action responses by fax caused the fax filing system to go down as well. Electronically, the USPTO was a black hole for filing.
Suddenly, law firms all across the US were facing the realization that they would have to file these applications by post office. The problem was, many of these firms haven’t filed by post office since the early 2000’s. How do you even do it? What are the rules? What post office can I use that will be open late enough? What do I need to do to ensure that I get my filing date?
The outage was so bad that the USPTO retroactively declared the day to count as a federal holiday, so as to give people an extra day to file any last-minute responses. This, however, does not help all cases. Some new application filings were running against a bar date on the 22nd, and the “holiday” clause would not have saved them.
In a time crunch lack of familiarity with even elementary steps can make the difference between being able to correctly complete the filing in a timely fashion.
Here at S+B, not only did we manage to file everything in time, but the situation also inspired the firm to implement a system where everyone, including the attorneys and partners, would periodically run one filing every other month as if we had to file it by mail.
We go through every step necessary to mail out a filing, including driving to the post office, printing documents, counting pages to make sure none are missing, as well as preparing the addressed packages and postcards. Because these steps are time-consuming and are not typically experienced on a daily basis by patent professionals of recent generations, each filing is timed to ensure we are prepared the next time the EFS is unavailable.
By periodically practicing these protocols, our team forms a familiarity with the specific tasks to be performed, so that everyone is trained to timely complete the filing.
Thinking from the end requires considering all possible scenarios, preparing for them, challenging ourselves, and always aiming at providing the best possible work product no matter the circumstances.
Jan 26, 2018
Biosoftware eligibility at USPTO: mere computations or improvement in technology?read more
Patents - January 26, 2018
Biosoftware eligibility at USPTO: mere computations or improvement in technology?
Bioinformatics has become an increasingly important tool in understanding biological processes and promoting and supporting progresses in molecular biology and many other areas of biology.
The related software involves massively complex calculations that predict the actions – folding, bonding, membrane translocation – of molecules. These software products are incredibly important in the biotech field – for example, drug design or protein folding.
And yet, in the wake of the Alice decision, we are observing a constant barrage of rejections from the USPTO under 35 USC 101 claiming that since bioinformatics methods are computational in nature and do not “improve the computer”, they are not eligible for patentability even if they are novel and non-obvious. A common point made in these 35 USC 101 rejections is that the software does not “improve the computer or computer technology.” However, it is important to remember that Alice also notes that method steps that “effect an improvement in any other technology or technical field” can satisfy the “significantly more” criteria for patentable subject matter. There is no apparent basis in Alice or other court decisions that would support a conclusion that if a method does not improve the computer” is not eligible for patent protection if it provides “an improvement in other technology or technical field”. Clearly, bioinformatics software improves the technical field of molecular biology.
Still, rejections of bioinformatics might be due to the way claims are written (of course) as well as due to the uncertainty or a narrow reading of what “effect and improvement in any other technology or technical field” means. Does it require a hardware component, like the thermocouple of Diamond v. Diehr? This seems unlikely, because the court in Alice didn’t say “effect an improvement in a machine of any other technology”. And wouldn’t an improvement to a “technological field” be broader than that?
Therefore, we draft claims in which the steps of an inventive biosoftware method are characterized by transformative technical features so that the steps and related combination are tailored to the specific features of the biological environment that is simulated, such as molecule modeling, changes in the related residues or moieties in view of environmental conditions, molecule interactions and the like.
However, what we sadly observe is that some Examiners of the USPTO look at bioinformatics software and can’t view the claims as being anything more than being “directed to” computations, data manipulations, and math – no matter how the claims are written.
The Examiner dismisses technical features such as representation of spatial locations of a biomolecule in a biological environment or representation of changes in such location due to molecule interactions with the environment, and just interprets those claims as processing information and converting one form of numerical representation into another by organizing information through “mathematical concepts such as mathematical algorithms, mathematical relationships, mathematical formulas, and calculations.
Such an approach de facto ignores looking at the claims “as a whole” and misses seeing the technical features of the claims – method steps that detail bioinformatics computations that specifically produce a result useful only to predicting the behavior of molecules – that lead the claim to actually being directed to an improvement to a technical field.
Additionally, the USPTO puts this software claims into a catch-22 scenario whereby the technical features included in the steps of the method claims are ignored and adding steps of using the results of the software (such as drug production) is dismissed as merely stating “apply it” to method, and the omission of such a step is pointed out as lacking some sort of “transformation” in the technical field.
If only the USPTO examiners would take a step back and look at how integrated claims written as indicated above and considered as a whole, are in the technical fields of bioinformatics and molecular biology, then they would agree that this type of software should be observed as satisfying the two-part test of Alice. Even if the Examiners still disagree, they need to point to the court cases that support their position, since the USPTO does not have the power to create new forms of judicial exception to patent eligibility.
Thankfully, there has been a recent indication that the USPTO might be going in this direction. In late November of 2017, there was a USPTO PTAB appeal decision (2017-003914; for application 13/822,231) where the Board stated that the examiners “”must be careful to avoid oversimplifying the claims” by looking at them generally and failing to account for the specific requirements of the claims” (quoting McRO). They also pointed out that the bioinformatics software claims were “focused on a specific articulated improvement in protein modeling” and were “distinguishable from those in Alice and related cases, in which the computer-implemented method was responsible for merely “organizing [existing] information into a new form” or carrying out a previously-known and fundamental economic practice.” Hopefully, this type of analysis will extend to other applications as well.
The IP portfolio of an entire sector of industry and R/D is being wiped out for no valid reason other than the grey morass that was left in the wake of Alice.
As USPTO Director Andre Iancu wrote in his paper “Machines and Transformations: The Past, Present, and Future Patentability of Software” (concerning the Bilski case), “Whatever the merits of various arguments regarding the patentability of business methods, the patentability of software processes, which are at the heart of innovation in our Information Age, at least deserves separate consideration.” And, likewise, we hope that the exclusion of economics-based software in Alice does not impede the patentability of technologically based software methods.
Dec 12, 2017
What has Design to do with Patents and Innovation? EVERYTHING.read more
S+B - December 12, 2017
What has Design to do with Patents and Innovation? EVERYTHING.
A patent designed to support the innovators’ needs and vision will have innovative power in itself and will become engine of growth for the innovators’ R&D and business.
Principles of Patent Design
Do not take the invention and the innovator for granted. Be aware that you need to learn and unlearn before drafting. Make room for the innovator’s vision.
Sharpen Your Insight
Use your knowledge to gain an accurate and deep understanding of the invention and the innovator. Understand what features are key to their inner workings and objectives.
Build a patent frame which operates on the invention’s and innovator’s key features to maximize their strengths and operability. Aim to remove limits and open possibilities.
Think from the End
Shape patent protection to fit the innovator’s ultimate goals. Don’t be afraid to ask questions and take a different point of view.
Strive for Excellence
Never settle for anything other than the best possible work product.
Oct 12, 2016
Patent cases in the Supreme Court’s October 2016 termread more
Patents - October 12, 2016
Patent cases in the Supreme Court’s October 2016 term
The Supreme Court will decide two patent cases on the merits in the October 2016 term of the Court. These cases are:
1. Samsung Electronics Co. v. Apple, Inc., ___ U.S. ___, 136 S. Ct. 1453, 194 L. Ed. 2d 549 (March 21, 2016) (granting petition for certiorari “limited to Question 2 presented by the petition”); and
2. SCA Hygiene Products Aktiebolag v. First Quality Baby Products, LLC, ___ U.S. ___, 136 S. Ct. 1824, 194 L. Ed. 2d 829 (May 2, 2016) (granting petition for certiorari).
The Court heard oral argument in the Samsung case on October 11, 2016. The official transcript of the argument is available here. The question presented for review is “[w]here a patented design is applied only to a component of a product, should an award of infringer’s profits be limited to profits attributable to that component?” This is the case in which Samsung’s entire profits from selling its accused smartphones were awarded to Apple for infringing Apple’s design patents for the front face of the iPhone and its graphical user interface. We published a news item, about the case when the Supreme Court decided to grant review earlier in 2016. We published an earlier news item, about the billion-dollar jury verdict in favor of Apple.
The SCA Hygiene case is set for oral argument on November 1, 2016. The question presented for review is “[w]hether and to what extent the defense of laches may bar a claim for patent infringement brought within the Patent Act’s six-year statutory limitations period, 35 U.S.C. § 286.” We published a news item, about the Supreme Court’s decision earlier in 2016 to take this case up for review. We also published a news item, about the decision en banc of the U.S. Court of Appeals for the Federal Circuit in this case. The Federal Circuit decided that the affirmative defense of laches (due to unreasonable delay by the plaintiff in bringing suit) was available in patent infringement lawsuits despite the existence of a six-year statute of limitations for collecting damages due to patent infringement.
Oct 06, 2016
Inter partes review 6: Cuozzo at the Supreme Courtread more
Patents - October 06, 2016
Inter partes review 6: Cuozzo at the Supreme Court
The Court heard argument (the argument’s audio is available here) on April 25, 2016 and less than two months later issued its judgment and opinion. Justice Breyer wrote the opinion for a unanimous Court with respect to parts I and III and for the Court for part II.
The Court addressed two issues in deciding the case. First, does 35 U.S.C. § 314(d) bar a court from considering whether the Patent Office wrongly determined to institute an inter partes review when it did so on grounds not specifically mentioned in a third party’s review request? The Court concluded that the first provision, though it may not bar consideration of a constitutional question, does bar judicial review of the kind of “mine-run” claim at issue in Cuozzo Speed Technologies, involving the Patent Office’s decision to institute inter partes review. (The Court sometimes uses the term “mine-run” when others likely would use the term “run of the mill.” The first time the Court did so was in Monroe v. Pape, 365 U.S. 167 (1961) (opinion for the Court written by Douglas, J.), and in forty-four cases since then).
The second issue is whether 35 U.S.C. § 316(a)(4) authorizes the Patent Office to issue a regulation stating that the agency, in inter partes review, shall construe a patent claim according to its broadest reasonable construction in light of the specification of the patent in which it appears. The Court concluded that the Patent Office was authorized to issue the regulation.
With respect to the first issue, Garmin’s petition for inter partes review asked the Patent Trial and Appeal Board (PTAB) to institute review of claim 17 of the Cuozzo patent. The PTAB ordered inter partes review of claims 10 and 14 as well and on the basis of the same prior art as for claim 17. The Patent Office argued that the claims 10, 14, and 17 were logically interlinked (claim 17 depends on claim 14 which in turn depends on claim 10) and “a petition need not simply repeat the same argument expressly when it is so obviously implied” even though 35 U.S.C. § 312 requires that a petition for inter partes review must identify, “in writing and with particularity, each claim challenged, the grounds on which the challenge to each claim is based.
The Court agreed, citing the language of 35 U.S.C. § 314(d), which states that the “determination by the [Patent Office] whether to institute an inter partes review under this section shall be final and nonappealable [emphasis added].” The Court also was persuaded by what it considered an important Congressional objective, namely, “giving the Patent Office significant power to revisit and revise earlier patent grants” which would be undercut if the “agency’s final decision could be unwound under some minor statutory technicality related to its preliminary decision to institute inter partes review.” Furthermore, “the existence of similar provisions in this, and related, patent statutes reinforces our conclusion,” namely the non-appealability of determinations concerning petitions for inter partes reexamination.
The Court noted that it applies a “strong presumption” in favor of judicial review when it interprets statutes, including statutes that may limit or preclude review. Nevertheless, the “No Appeal” provision’s language forbids an appeal that attacks a determination whether to institute review because it is “an ordinary dispute about the application of certain relevant patent statutes concerning the Patent Office’s decision to institute inter partes review.” Thus, “we emphasize that our interpretation applies where the grounds for attacking the decision to institute inter partes review consist of questions that are closely tied to the application and interpretation of statutes related to the Patent Office’s decision to initiate inter partes review.”
The Court left open appeals from determinations whether to institute review based upon disputes that are not ordinary. “[W]e need not, and do not, decide the precise effect of §314(d) on appeals that implicate constitutional questions, that depend on other less closely related statutes, or that present other questions of interpretation that reach, in terms of scope and impact, well beyond ‘this section.’” Thus, the Court does not categorically preclude review of a final decision where a petition fails to give “sufficient notice” such that there is a due process problem with the entire proceeding, nor does its interpretation enable the agency to act outside its statutory limits by, for example, canceling a patent claim for “indefiniteness under §112” in inter partes review. (A petition for inter partes reviews must be based only on a ground under 35 U.S.C. §§ 102 or 103 and only on the basis of prior art. 35 U.S.C. § 311(b).)
Justice Alito, joined by Justice Sotomayor, filed an opinion concurring in part but dissenting in part with respect to whether the Patent Trial and Appeal Board’s decision to institute inter partes review is subject to judicial review. The Court dismissed the argument in Justice Alito’s opinion that the “No Appeal” provision forbids only interlocutory appeals but permits review of the decision to grant a petition during a final appeal from a decision on the merits.
With respect to the second issue, Cuozzo argued that the Patent Office lacked the legal authority to issue its regulation requiring the agency, when conducting an inter partes review, to give a patent claim “its broadest reasonable construction in light of the specification of the patent in which it appears.” 37 C.F.R. § 42.100(b). (The Patent Office amended this regulation on April 1, 2016 to add this alternative:“[a] party may request a district court-type claim construction approach to be applied if a party certifies that the involved patent will expire within 18 months from the entry of the Notice of Filing Date Accorded to Petition.”) Cuozzo contended that the Patent Office should, like the courts, give claims their “ordinary meaning . . . as understood by a person of skill in the art.”
The Court, however, pointed out that the statute contains a provision that grants the Patent Office authority to issue “regulations . . . establishing and governing inter partes review under this chapter.” 35 U.S.C. § 316(a)(4). The Court held that this statute gives the Patent Office the legal authority to issue its broadest reasonable construction regulation. The Court interpreted Congress’ grant of rulemaking authority in light of the Court’s decision in Chevron U. S. A. Inc. v. Natural Resources Defense Council, Inc., 467 U. S. 837, 842 (1984).
The “Chevron deference” doctrine requires that when a statute is clear, an agency must follow the statute, but when a statute leaves a gap or is ambiguous, the Court typically interprets it as granting the agency leeway to enact rules that are reasonable in light of the text, nature, and purpose of the statute. The Court has “recognized a very good indicator of delegation meriting Chevron treatment in express congressional authorizations to engage in the process of rulemaking or adjudication that produces regulations or rulings for which deference is claimed.” United States v. Mead Corp., 533 U. S. 218, 229 (2001). The statute allows the Patent Office to issue rules “governing inter partes review,” 35 U.S.C . § 316(a)(4), and the broadest reasonable construction regulation is a rule that governs inter partes review.
The Court therefore found an express delegation of rulemaking authority, a “gap” that rules might fill, and “ambiguity” in respect to the boundaries of that gap. Applying Chevron deference, the Court concluded that that the regulation represented a reasonable exercise of the rulemaking authority that Congress delegated to the Patent Office.
Cuozzo and the Federal Circuit judges that dissented from the denial of en banc review argued that an inter partes review was like (or a surrogate for) patent litigation in the district courts because of similarities in procedure and the fact that a decision to cancel patent claims normally has the same effect as a district court’s determination of invalidity of patent claims. They argued the PTAB should apply the standard of construction of patent claims used in court, namely, the ordinary meaning construction. The Court disagreed with this argument because “in other significant respects, inter partes review is less like a judicial proceeding and more like a specialized agency proceeding” and the “purpose of the [inter partes review] proceeding is not quite the same as the purpose of district court litigation.”
In the examination of patent applications the broadest reasonable construction is properly employed to protect the public from overly broad claims and give the applicant a fair chance to draft a precise claim that will qualify for patent protection. Cuozzo argued that in inter partes review the broadest reasonable construction standard may help protect certain public interests, but the patent owner has no absolute right to amend any challenged patent claims. The Court was not impressed with this argument because “[t]he process however, is not as unfair as Cuozzo suggests. The patent holder may, at least once in the process, make a motion to do just what he would do in the examination process, namely, amend or narrow the claim.” That motions to amend claims in inter partes review proceedings are rarely granted “may reflect the fact that no amendment could save the inventions at issue, i.e., that the patent should have never issued at all” (at least with those claims).
Cuozzo also argued that the use of the broadest reasonable construction standard in inter partes review, together with use of an ordinary meaning standard in district court, might produce inconsistent results and cause added confusion. Thus, a district court may find a patent claim to be valid, and the agency may later cancel that claim. The Court agreed that this could happen but its possibility, however, has long been present in the patent system with its different tracks for the review and adjudication of patent claims. The different burdens of proof on the challenger in the courts as compared to inter partes review mean that “the possibility of inconsistent results is inherent to Congress’ regulatory design.”
Justice Thomas filed a concurring opinion in Cuozzo expressing his desire (expressed previously, see, e.g., Michigan v. Environmental Protection Agency, 576 U.S. ___, 135 S. Ct. 2699, 2712, 192 L. Ed. 2d 674 (2015) (Thomas, J. concurring)) that “this Court should reconsider that fiction of Chevron and its progeny.” He concurred in the judgment in Cuozzo, however, because he believed the Court effectively asked whether the rulemaking was “arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law,” in conformity with the Administrative Procedure Act, 5 U. S. C. § 706(2)(A).
Oct 06, 2016
Inter partes review 7: Motions to amend study and casesread more
Patents - October 06, 2016
Inter partes review 7: Motions to amend study and cases
The study concluded that the TTAB had conducted 192 trials of inter partes review proceeding in which the patent owner filed motions to amend the claims. Due to settlement, original claims being held patentable, and the motions being solely to cancel claims (easily granted), the TTAB actually decided motions to amend in 118 trials. Two of those motions were granted and four granted in part. The TTAB therefore denied ninety-five percent of the motions to amend.
The Federal Circuit recently decided for the first time that the PTAB was wrong to deny a motion to amend the claims. In Veritas Techs. LLC v. Veeam Software Corp., ___ F.3d ___, 2016 U.S. App. LEXIS 15978 (Fed. Cir. August 30, 2016) the court vacated the PTAB’s denial of the patent owner’s motion to conditionally amend the claims because the Board’s decision was “arbitrary, capricious, or otherwise not in accordance with the law” under the Administrative Procedures Act (specifically, 5 U.S.C. § 706(2)(A)).
The standards for motions to amend the claims in inter partes review actions, and how the PTAB should act if the patent challenger does not contest such a motion or does so inadequately, are the subject of a rehearing en banc by the Federal Circuit. In re Aqua Products, Inc., 2016 U.S. App. LEXIS 14862, 119 U.S.P.Q. 2d (BNA) 1882 (Fed. Cir. August 12, 2016)(vacating the panel opinion reported at 823 F.3d 1369 (Fed. Cir. May 25, 2016) and granting motion for rehearing en banc). The questions for briefing are:
- When the patent owner moves to amend its claims under 35 U.S.C. § 316(d), may the PTO require the patent owner to bear the burden of persuasion, or a burden of production, regarding patentability of the amended claims as a condition of allowing them? Which burdens are permitted under 35 U.S.C. § 316(e)?
- When the petitioner does not challenge the patentability of a proposed amended claim, or the Board thinks the challenge is inadequate, may the Board sua sponte raise patentability challenges to such a claim? If so, where would the burden of persuasion, or a burden of production, lie?